The medical guidelines for childhood LCH have been published in Pediatric Blood & Cancer  (PBC), Wiley Online Library.

More ...
An­nu­al in­ter­na­tio­nal con­fe­rence of sci­en­tists, pa­tho­lo­gists and cli­ni­ci­ans discussing histiocytoses and their backgrounds. More ...
An International Community of Professionals Dedicated to Research and Treatment More ...
PubMed comprises more than 20 million citations for biomedical literature from MEDLINE, life science journals, and online books. More ...

European Union Clinical Trials Register of the European Medicines Agency

More ...

European Clinical Trials Database of the European Medicines Agency

More ...
Rare diseases in EU
Why do rare diseases need specific EU support? More ...
Euro Histio Net has received funding from the European Union, in the framework of the Public Health Programme. More ...
 
» Expert Histio Net » For Professionals » Guidelines » LCH childhood » Clinical Classification  · 

Clinical Classification

Author(s): Euro Histio Net Work Group for LCH Guidelines (see introduction page), Created: 2011/03/10, last update: 2014/02/09

Treatment recommendations are based on site and extension of the disease which is why it is important to distinguish between single system LCH and multisystem LCH.

Single System LCH (SS-LCH)

One organ/system involved (uni- or multifocal):

  • Bone: unifocal (single bone) or multifocal (> 1 bone)
  • Skin
  • Lymph node (not the draining lymph node of another LCH lesion)
  • Lungs
  • Hypothalamic-pituitary / Central nervous system
  • Other (e.g. thyroid, thymus)

Multisystem LCH (MS-LCH)

Two or more organs/systems involved:

  • With involvement of “Risk Organs” (Hematopoietic system, spleen, and/or liver)
  • Without involvement of “Risk Organs”

Note: Other systems have also been proposed in order to classify disease extension. In particular the so called “activity score” has been proposed [Donadieu et al 2004a] and is still in use in some countries such as in France. This system provides a score (0 no activity, up to 5 maximum activity) for each organ or system possibly affected by LCH. The score can be measured at diagnosis as at any follow-up visit. A total score > 6 is considered as unfavorable, as well as any worsening of previous scores.

See here the definition of organ involvement.
Possibly involved organs: bone, skin, hematopoietic system, spleen, liver, lung, mucosea, eye, ear, pituitary, CNS, other; risk organs; special sites
References

[Donadieu et al 2004a] Donadieu J, Piguet C, Bernard F, Barkaoui M, Ouache M, Bertrand Y, Ibrahim H, Emile JF, Hermine O, Tazi A, Genereau T, Thomas C: A new clinical score for disease activity in Langerhans cell histiocytosis. Pediatric blood & cancer 2004, 43: 770 [PMID: 15390280]